Highlights
Background
Methods
Data collection
Characters | Test group (n = 208) | Control group (n = 204) |
---|---|---|
Age group, years | ||
< 60 | 96 (46.2%) | 95 (46.6%) |
≥ 60 | 112 (53.8%) | 109 (53.4%) |
Gender | ||
Male | 135 (64.9%) | 124 (60.8%) |
Female | 73 (35.1%) | 80 (39.2%) |
Smoking history | ||
Never smoker | 29 (13.9%) | 23 (11.3%) |
Former smoker | 81 (39.0%) | 88 (43.1%) |
Current smoker | 98 (47.1%) | 93 (45.6%) |
KPS score | ||
60–75 | 80 (38.5%) | 84 (41.2%) |
> 75 | 128 (61.5%) | 120 (58.8%) |
Metastasis | ||
Yes | 99 (47.6%) | 96 (47.1%) |
No | 109 (52.4%) | 108 (52.9%) |
Disease staging | ||
I-II | 113 (54.3%) | 106 (52.0%) |
III-IV | 95 (45.7%) | 98 (48.0%) |
Classification | ||
SCLC | 44 (21.2%) | 40 (19.6%) |
NSCLC | 164 (78.8%) | 164 (80.4%) |
NSCLC type | ||
LADC | 109 (66.5%) | 108 (65.9%) |
LSCC | 55 (33.5%) | 56 (34.1%) |
Therapeutic schedules
Systemic chemotherapy
Bronchoscopic interventional cryotherapy
Evaluation indexes
Follow-up visit
Statistics analysis
Results
Short-term effects
Project | CR | PR | SD | PD | ORR | DCR |
---|---|---|---|---|---|---|
Test group (n = 208) | 108 (51.9) | 42 (20.2) | 40 (19.2) | 18 (8.7) | 72.1 | 91.3 |
Control group (n = 204) | 56 (27.5) | 60 (29.4) | 40 (19.6) | 48 (23.5) | 56.9 | 76.5 |
P Value | 0.027 | 0.004 |
Project | CR | PR | SD | PD | ORR | DCR |
---|---|---|---|---|---|---|
SCLC (n = 44) | 9 (20.5) | 12 (27.3) | 14 (31.8) | 9 (20.4) | 47.8 | 78.9 |
NSCLC (n = 164) | 99 (60.4) | 30 (18.3) | 26 (15.8) | 9 (5.5) | 78.7 | 94.5 |
P Value | < 0.0001 | 0.002 | ||||
LADC (n = 109) | 70 (64.2) | 19 (17.4) | 15 (13.8) | 5 (4.6) | 81.6 | 95.4 |
LSCC (n = 55) | 29 (52.7) | 11 (20) | 11 (20) | 4 (7.3) | 72.7 | 92.7 |
P Value | 0.13 | 0.55 |
Serum tumor marker levels between the two groups
Project | Test group (n = 208) | Control group (n = 204) | P Value |
---|---|---|---|
Before treatment | |||
CEA (ng/ml) | 96.27 ± 9.57 | 95.38 ± 9.21 | 0.34 |
NSE (ng/ml) | 88.62 ± 7.52 | 88.01 ± 7.44 | 0.41 |
CYFRA21-1 (ng/ml) | 37.84 ± 5.90 | 37.58 ± 6.00 | 0.66 |
CA199 U/ml | 51.83 ± 7.53 | 50.69 ± 7.42 | 0.12 |
After treatment | |||
CEA (ng/ml) | 22.68 ± 3.53 | 56.53 ± 7.51 | < 0.0001 |
NSE (ng/ml) | 25.59 ± 4.53 | 58.19 ± 8.63 | < 0.0001 |
CYFRA21-1 (ng/ml) | 9.88 ± 0.55 | 22.08 ± 2.37 | < 0.0001 |
CA199 U/ml | 27.15 ± 4.69 | 47.95 ± 4.56 | < 0.0001 |
Project | SCLC | NSCLC | P Value | LADC | LSCC | P Value |
---|---|---|---|---|---|---|
Before treatment | ||||||
CEA (ng/ml) | 96.73 ± 9.11 | 96.01 ± 9.31 | 0.65 | 95.54 ± 9.78 | 95.82 ± 9.12 | 0.86 |
NSE (ng/ml) | 88.71 ± 7.43 | 88.61 ± 7.51 | 0.94 | 88.63 ± 7.49 | 88.59 ± 7.49 | 0.97 |
CYFRA21-1 (ng/ml) | 37.87 ± 5.87 | 37.84 ± 5.90 | 0.98 | 37.82 ± 5.88 | 37.85 ± 5.89 | 0.96 |
CA199 U/ml | 51.78 ± 7.48 | 51.84 ± 7.52 | 0.96 | 51.82 ± 7.52 | 51.85 ± 7.51 | 0.98 |
After treatment | ||||||
CEA (ng/ml) | 24.66 ± 1.55 | 20.25 ± 1.1 | < 0.0001 | 20.27 ± 1.08 | 20.24 ± 1.09 | 0.87 |
NSE (ng/ml) | 28.15 ± 1.97 | 22.81 ± 1.75 | < 0.0001 | 22.83 ± 1.73 | 22.79 ± 1.73 | 0.89 |
CYFRA21-1 (ng/ml) | 10.13 ± 0.13 | 9.55 ± 0.22 | < 0.0001 | 9.54 ± 0.21 | 9.57 ± 0.2 | 0.38 |
CA199 U/ml | 29.22 ± 2.62 | 24.16 ± 1.7 | < 0.0001 | 24.14 ± 1.72 | 24.17 ± 1.71 | 0.92 |
The levels of serum MMP and T cell subsets between the two groups
Project | Test group (n = 208) | Control group (n = 204) | P Value |
---|---|---|---|
Before treatment | |||
MMP-2 (ng/L) | 182.51 ± 12.66 | 180.36 ± 12.92 | 0.09 |
MMP-9 (ng/L) | 207.24 ± 22.50 | 203.31 ± 23.11 | 0.08 |
CD4+ % | 33.15 ± 4.24 | 33.12 ± 4.13 | 0.94 |
CD8+ % | 30.51 ± 3. 39 | 30.76 ± 3.54 | 0.46 |
CD4+/CD8+ | 1.17 ± 0. 25 | 1.18 ± 0.21 | 0.66 |
After treatment | |||
MMP-2 (ng/L) | 32.51 ± 4.11 | 76.37 ± 6.39 | < 0.0001 |
MMP-9 (ng/L) | 34.38 ± 4.82 | 77.13 ± 7.09 | < 0.0001 |
CD4+ % | 37.82 ± 5.12 | 33.73 ± 4.73 | < 0.0001 |
CD8+ % | 27.05 ± 3.83 | 29.18 ± 3.10 | < 0.0001 |
CD4+/CD8+ | 1.33 ± 0.21 | 1. 16 ± 0. 20 | < 0.0001 |
Project | SCLC | NSCLC | P Value | LADC | LSCC | P Value |
---|---|---|---|---|---|---|
Before treatment | ||||||
MMP-2 (ng/L) | 182.93 ± 12.24 | 181.52 ± 11.67 | 0.48 | 180.22 ± 10.37 | 181.05 ± 12.14 | 0.65 |
MMP-9 (ng/L) | 206.17 ± 21.43 | 207.88 ± 21.86 | 0.64 | 207.61 ± 21.59 | 208.20 ± 21.54 | 0.87 |
CD4+% | 33.63 ± 3.76 | 33.00 ± 4.09 | 0.36 | 32.55 ± 3.64 | 33.17 ± 3.93 | 0.32 |
CD8+% | 30.87 ± 3.03 | 30.46 ± 3.34 | 0.46 | 30.25 ± 3.13 | 30.77 ± 3.03 | 0.31 |
CD4+/CD8+ | 1.20 ± 0.22 | 1.15 ± 0.23 | 0.20 | 1.17 ± 0.21 | 1.13 ± 0.21 | 0.25 |
After treatment | ||||||
MMP-2 (ng/L) | 35.6 ± 1.02 | 30.52 ± 2.12 | < 0.0001 | 30.71 ± 2.31 | 30.78 ± 1.86 | 0.85 |
MMP-9 (ng/L) | 35.37 ± 1.25 | 31.08 ± 1.52 | < 0.0001 | 31.13 ± 1.47 | 30.86 ± 1.3 | 0.25 |
CD4+% | 38.15 ± 4.97 | 37.78 ± 5.08 | 0.66 | 37.33 ± 4.63 | 37.81 ± 5.05 | 0.54 |
CD8+% | 27.22 ± 3.66 | 26.93 ± 3.71 | 0.64 | 26.51 ± 3.29 | 27.13 ± 3.51 | 0.27 |
CD4+/CD8+ | 1.36 ± 0.18 | 1.33 ± 0.21 | 0.39 | 1.30 ± 0.18 | 1.34 ± 0.20 | 0.20 |